How big is CureVac NV?

As of Jun 18, CureVac NV has a market capitalization of 1,238.36 million, with net sales of 574.48 million and a net profit of 203.49 million over the latest four quarters. The company reported shareholder's funds of 721.34 million and total assets of 831.33 million as of Dec 24.

Market Cap: As of Jun 18, CureVac NV has a market capitalization of 1,238.36 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, CureVac NV reported net sales of 574.48 million and a net profit of 203.49 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 721.34 million and total assets of 831.33 million.

What does CureVac NV do?

CureVac NV is a Germany-based biotechnology company focused on developing mRNA and RNA-based vaccines for infectious diseases, cancer, and rare diseases. As of March 2025, it reported net sales of $1 million and a net loss of $55 million, with a market cap of $1.24 billion.

Overview:<BR>CureVac NV is a Germany-based biotechnology company engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines, focusing on vaccines for infectious diseases and treatments for cancer and rare diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -55 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,238.36 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: 5.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.67 <BR>Return on Equity: 29.24% <BR>Price to Book: 1.77 <BR><BR>Contact Details:<BR>Address: Friedrich-Miescher-Str. 15, TUEBINGEN None: 72076 <BR>Tel: 49 7071 98830 <BR>Fax: 49 7071 98831101

Should I buy, sell or hold CureVac NV?

Is CureVac NV technically bullish or bearish?

As of August 18, 2025, CureVac NV's trend is mildly bullish with mixed technical indicators, strong year-to-date performance of 56.89%, but negative long-term returns compared to the S&P 500.

As of 18 August 2025, the technical trend for CureVac NV has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The Bollinger Bands are bullish on the weekly and mildly bullish on the monthly, supporting a positive outlook. Daily moving averages are mildly bullish, suggesting some short-term strength. However, the KST is mildly bearish on the weekly and bullish on the monthly, adding to the mixed sentiment. <BR><BR>CureVac has shown strong performance year-to-date with a return of 56.89%, significantly outperforming the S&P 500's 12.22%. Over the past year, it also outperformed the benchmark with a return of 62.61% compared to the S&P 500's 17.14%. However, longer-term returns over 3, 5, and 10 years are notably negative compared to the S&P 500. Overall, the current stance is mildly bullish, driven by the mixed indicators and strong recent performance.

Is CureVac NV overvalued or undervalued?

As of October 24, 2025, CureVac NV is considered a very attractive investment due to its undervaluation indicated by a P/E ratio of 5, an EV to EBITDA of 1.90, and a PEG ratio of 0.03, despite a long-term decline of 89.29% over five years, while outperforming the S&P 500 with a year-to-date return of 57.18%.

As of 24 October 2025, the valuation grade for CureVac NV has moved from attractive to very attractive, indicating a strong improvement in its perceived value. The company is currently considered undervalued, supported by a P/E ratio of 5, an EV to EBITDA of 1.90, and a PEG ratio of 0.03, which suggests significant growth potential relative to its price. <BR><BR>In comparison to its peers, CureVac NV's P/E ratio is notably lower than PTC Therapeutics, Inc. at 5.85 and Harmony Biosciences Holdings, Inc. at 11.40, reinforcing its undervaluation. Additionally, while CureVac has experienced a year-to-date return of 57.18%, significantly outperforming the S&P 500's return of 15.47%, its long-term performance over the past five years shows a decline of 89.29%, highlighting volatility. Overall, these metrics suggest that CureVac NV is positioned as an attractive investment opportunity within the pharmaceuticals and biotechnology sector.